Precision Medicine in Oncology®

Improving the accuracy and value of tumor marker testing in patients with breast cancer has resulted in a dramatic upswing in accredited laboratories and the clarification of guideline definitions.

During the past 40 years, the concept of thwarting a tumor by attacking its blood supply has become a central thrust of cancer research, a strategy that reached a milestone with the approval of bevacizumab in 2004.

Dr. Giorgio V. Scagliotti from the University of Turin on Mechanisms of Resistance to EGFR TKIs

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses the Development of Combination Therapies

Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.

Dr. Corey J. Langer from Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab

Leading breast cancer researcher Joyce A. O'Shaughnessy, MD, developed and chaired the 10th International Congress on the Future of Breast Cancer, a 4-day interactive program.

Nita Maihle, PhD, is a professor of Obstetrics, Gynecology and Reproductive Sciences, and director of a clinically oriented cancer research laboratory at Yale University, New Haven, Connecticut.

Dr. Hope S. Rugo from University of California, San Francisco on Proliferation as an Anti-Angiogenesis Marker

Professor of Surgery and Consultant Surgeon at the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland.

Dr. Corey J. Langer from Abramson Cancer Center on Assessing Patient Populations in Clinical Trials

Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

Dr. Gordon Mills from MD Anderson Cancer Center Explains the Vulnerability of Cancer Cells

Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center Describes the ACOSOG Z11 Trial

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine

Dr. Michael Dixon from University of Edinburgh on Systems Biology Determining Therapy Combinations

Dr. Giorgio Scagliotti from the University of Turin in Italy on EGFR Targeted Therapy Survival Benefits

Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment

T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.

In vitro cell manipulation has unleashed the therapeutic potential of human cells.

Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity

Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy